×
About 7,483 results

High-Dose Marine Omega-3s Raise Risk for Atrial Fibrillation
https://www.medscape.com/viewarticle/961473

Nov 17th, 2021 - This transcript has been edited for clarity. Hello. This is Dr JoAnn Manson, professor of medicine at Harvard Medical School and Brigham and Women's Hospital. I'd like to talk with you about a recent report in Circulation: a meta-analysis of randomized clinical trials of the marine omega-3 fatty acids and risk for atrial fibrillation (AF). The report was led by Dr Baris Spencer from Geneva, Swi...

Tofacitinib Postmarketing Data Shed Light on JAK Inhibitor Risks
https://www.medscape.com/viewarticle/963183

Nov 17th, 2021 - Additional analyses of a postmarketing trial that was required after the Food and Drug Administration's approval of the Janus kinase inhibitor tofacitinib (Xeljanz, Xeljanz XR) has identified characteristics of older patients with rheumatoid arthritis with at least one cardiovascular risk factor who may be at higher risk for major adverse cardiovascular events (MACE) when taking the drug. Resul...

How to Improve Dyslipidemia Care in Underresourced Populations
https://www.medscape.com/viewarticle/958746

Nov 15th, 2021 - This transcript has been edited for clarity. Laurence Sperling, MD: Welcome to Medscape's InDiscussion series on dyslipidemia. This is episode three. Today we'll be focusing on the impact of social determinants of health on lipid management, a critically important topic. I'd like to start off with a case that I think is relevant. This is a case of Mrs S who's 62 years old. She's a Black Hispani...

Call for Tighter LDL Targets for Highest Risk Patients
https://www.medscape.com/viewarticle/962914

Nov 15th, 2021 - LONDON - Tighter low-density lipoprotein (LDL) targets, should be the aim in very high-risk patients, using a combination of therapies in a new era of ‘ones not twos’ (in terms of mmol/L), according to experts in lipid and cardiovascular risk management.  "We underestimate residual cardiovascular risk in people living with type 2 diabetes, and despite aggressive management of blood pressure, li...

Anti-Inflammatory Therapy Linked to Reduction of CV Events
https://www.medscape.com/viewarticle/962932

Nov 15th, 2021 - This is a summary of a preprint research study by Zhi-Lu Wang and colleagues from The First Hospital of Lanzhou University on Research Square, provided to you by Medscape. This study has not yet been peer-reviewed. The full text of the study can be found on Researchsquare.com. Key Takeaway Patients with coronary artery disease (CAD) who received anti-inflammatory therapy had significantly lower...

At 5 Years, iFR Found as Effective and Safe as FFR for Guiding PCI Intervention
https://www.medscape.com/viewarticle/962723

Nov 11th, 2021 - The rate of major adverse cardiac events (MACE) over 5 years is similar whether revascularization is guided by instantaneous wave-free ratio (iFR) or fractional flow reserve (FFR), according to long-term results of the iFR-SWEDEHEART study. "The results are about the same as reported at 12 months. There were no significant differences in any outcome we evaluated," according to Matthias Götberg,...

Common Drugs Affect How Cells Respond to the Flu Virus
https://www.medscape.com/viewarticle/962775

Nov 11th, 2021 - Some common medications for chronic conditions could affect what the flu virus does to human cells, new research suggests. In findings published in Viruses , researchers have identified a cholesterol medication as well as antidepressants and an antihistamine that change how cells respond to the virus. The results could be important because people most likely to experience influenza complication...

Statins' Effects on CVD Outweigh Risk for Diabetes in RA
https://www.medscape.com/viewarticle/962643

Nov 10th, 2021 - The use of statins by patients with rheumatoid arthritis appears to provide an overall net benefit on cardiovascular disease outcomes that outweighs the risk of type 2 diabetes mellitus (T2DM) seen with the drugs in the general population, according to evidence from a cohort study of more than 16,000 people in the United Kingdom that was presented at the virtual annual meeting of the American C...

Treating Young Adults With High LDL May Be Cost-Effective
https://www.medscape.com/viewarticle/962514

Nov 8th, 2021 - Treating elevated low-density lipoprotein cholesterol (LDL-C) in adults younger than 40 with statins is highly cost-effective in men, and intermediately cost-effective in women, a new report suggests. In a simulated model based on data from the US National Health and Nutrition Examination Survey (NHANES), lipid lowering with statins or lifestyle interventions in this age group would prevent or ...

Vitamin D and Omega-3 Supplements Reduce Autoimmune Disease Risk
https://www.medscape.com/viewarticle/962462

Nov 7th, 2021 - For those of us who cannot sit in the sun and fish all day, the next best thing for preventing autoimmune diseases may be supplementation with vitamin D and fish oil derived omega-3 fatty acids, results of a large prospective randomized trial suggest. Dr Karen Costenbader Among nearly 26,000 adults enrolled in a randomized trial designed primarily to study the effects of vitamin D and omega-3 s...

SUGAR Trial Finds Superior Stent for Those With Diabetes and CAD
https://www.medscape.com/viewarticle/962426

Nov 5th, 2021 - Designed to show noninferiority for treatment of coronary artery disease (CAD) in patients with diabetes, a head-to-head comparison of contemporary stents ended up showing that one was superior to the for the primary endpoint of target lesion failure (TLF). In the superiority analysis, the 35% relative reduction in the risk of TLF at 1 year for the Cre8 EVO (Alvimedica) stent relative to the Re...

More Than Half of People Living With HIV Have Coronary Plaque
https://www.medscape.com/viewarticle/962421

Nov 5th, 2021 - More than half of people living with HIV and suppressed viral loads nonetheless had imaging-confirmed coronary artery disease — and despite longtime use of HIV drugs that have been associated with cardiovascular trouble, none of those drugs were implicated in disease risk in this study. "Traditional risk factors and duration of HIV infection was associated with severe coronary artery disease," ...

AHA Guidance Provides 10 Evidence-Based Diet Recommendations
https://www.medscape.com/viewarticle/962370

Nov 5th, 2021 - In a new scientific statement on diet and lifestyle recommendations, the American Heart Association is highlighting, for the first time, structural challenges that impede the adoption of heart-healthy dietary patterns. This is in addition to stressing aspects of diet that improve cardiovascular health and reduce cardiovascular risk, with an emphasis on dietary patterns and food-based guidance b...

AHA Statement Offers Strategies to Promote Healthy Lifestyle
https://www.medscape.com/viewarticle/962048

Nov 2nd, 2021 - Two new science advisories from the American Heart Association (AHA) provide clinicians with strategies and special considerations for the promotion of a healthy lifestyle in everyday clinical practice. Penny Kris-Etherton "It is clear that healthy lifestyle practices can have a big impact on reducing cardiovascular disease (CVD) risk. However, many Americans fall short in meeting Life's Simple...

Which Patients With Type 2 Diabetes Need SGLT2 Inhibitors?
https://www.medscape.com/viewarticle/961773

Oct 28th, 2021 - Agents that form the sodium-glucose cotransporter 2 inhibitor class – including canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance) – have show remarkably consistent cardiovascular efficacy and safety for treating patients with heart failure, chronic kidney disease, and higher-risk patients with type 2 diabetes. But despite an essential role now established for drug...

Lipid-Modifying Agents to Treat or Prevent COVID-19?
https://www.medscape.com/viewarticle/961588

Oct 26th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center Work exploring the potential use of lipid-modulating agents for the prevention and treatment of COVID-19 infection is ongoing. A new analysis has identified and reviewed 40 randomized clinical trials (RCTs) investigating the potential use of such agent, including statins, omega-3 fatty acids, fib...

Familial Hypercholesterolemia — Hiding in Plain Sight
https://www.medscape.com/viewarticle/958283

Oct 21st, 2021 - This transcript has been edited for clarity. Laurence Sperling, MD: Welcome to the Medscape InDiscussion podcast series on dyslipidemia. This is the first of six episodes. To launch this series today, we will focus on an extremely important topic: living with hypercholesterolemia and listening for clues of genetic risk. This topic is central to this series. First, a case presentation. A 38-year...

Pandemic Flips Script on Patient-Partnered Dyslipidemia Care
https://www.medscape.com/viewarticle/958311

Oct 21st, 2021 - This transcript has been edited for clarity. Laurence Sperling, MD: Welcome to Medscape's InDiscussion series on dyslipidemia. This is episode 2. Today, we'll be focusing on patient-partnered care, optimizing the care team, and the promise of telehealth. This topic is highly relevant. We've been living during challenging times, and during these challenging times, I hope we've learned some lesso...

Smoking a 'Major Driver' of Worse Outcomes After Traumatic Brain Injury
https://www.medscape.com/viewarticle/961231

Oct 20th, 2021 - Vascular risk factors, smoking in particular, are associated with worse outcomes following traumatic brain injury (TBI), new research shows. Dr Andrea Schneider "The big takeaway here is that smoking appears to be a really big driver of adverse outcomes after TBI," study investigator Andrea Schneider, MD, PhD, assistant professor of neurology, University of Pennsylvania Division of Neurocritica...

High-Dose Omega-3s Tied to Higher Risk for Atrial Fibrillation
https://www.medscape.com/viewarticle/960606

Oct 11th, 2021 - Taking high-doses of marine omega-3 fatty acids, more than 1 gram daily, may raise the risk for atrial fibrillation (AF), according to a meta-analysis of relevant research.  However, the risk of developing AF appears to be "relatively small" for those taking 1 gram or less of fish oil per day, Christine Albert, MD, chair of the  Department of Cardiology at the Smidt Heart Institute at Cedars-Si...